The Need for a Multi-Target CAR-T Platform

Acute Myeloid Leukemia (AML) has a low survival rate, and single-target CAR-T therapies often face challenges due to antigen escape, leading to high relapse rates. To address this, Shenzhen Geno-Immune Medical Institute is developing a multi-target CAR-T therapy targeting CLL-1 (CLEC12A) and CD123 or CD33 simultaneously, and has initiated a Phase 1/2 clinical trial. This represents a next-generation strategy aimed at overcoming treatment resistance by blocking multiple mutation pathways in cancer cells. By leveraging the unique characteristic of CLL-1, which is expressed only in leukemia stem cells (LSCs) and not in normal hematopoietic stem cells (HSCs), the therapy aims to reduce side effects.

Technical Features of the 4SCAR Platform

The technology used in this clinical trial is based on the institute's proprietary 4th-generation safety design (4SCAR) platform. This platform incorporates multiple costimulatory domains to enhance cell membrane signaling, thereby improving in vivo survival. To ensure safety, the therapy is equipped with an inducible Caspase 9 (iCasp9) switch, which can immediately induce cell death in treated cells in case of adverse events such as Cytokine Release Syndrome (CRS). This is a key technology that enables the management of acute toxicity, a major challenge in blood cancer CAR-T therapy.

Global AML Market Size Analysis

In 2026, the global market size for AML therapies is estimated at approximately USD 3.91 billion, and it is projected to grow at a compound annual growth rate of 10.75% to reach approximately USD 9.79 billion by 2034. The aging population and increasing demand for precision medicine are accelerating market growth, but the options for second-line standard-of-care treatments for relapsed patients are limited. With few alternatives to chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT), there is a high demand for safe cell therapies.

Competitive Pipeline Comparison

Currently, Baylor College of Medicine is conducting a Phase 1 clinical trial (NCT04219163) for a single-target CLL-1 CAR-T therapy. However, the single-target approach has a clear limitation in that cancer cells can evade treatment by suppressing the expression of specific antigens, making a multi-target approach more likely to offer a competitive advantage. Shenzhen Geno-Immune's multi-target CAR-T therapy uses either co-administration or simultaneous targeting of CLL-1 and CD123/CD33 to block the escape routes of cancer cells, and is expected to yield superior clinical results.

Investment Perspective: Outlook and Risks

The Phase 1/2 trial (NCT04010877) has a target enrollment of 10 patients and is scheduled for primary completion in July 2028, so it is important to monitor the data release schedule. Although the institute is not publicly listed, direct investment is difficult, the success of the proof-of-concept for the platform will stimulate global technology transfer demand. In the long term, improving the manufacturing process and demonstrating the clinical value as a bridge therapy before hematopoietic stem cell transplantation will be key to commercialization.